Company intelligence / Profile preview

Actuate Therapeutics

Fort Worth, Texas, United Statesactuatetherapeutics.com ↗

Ownership: Public · ACTU
Employees: ~10
Development stage: Phase 2

Overview

Positive interim Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) announced in December 2024. The primary endpoint is 1-year survival rate. The trial enrolled 286 mPDAC patients randomized 2:1 to the elraglusib treatment arm or control arm.

Therapeutic areas: Oncology
Modalities: Small molecules (GSK-3β inhibitor)
Industry: Biotech

Drug pipeline

2 assets

elraglusib

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $32.8M
Total revenue: $0
Enterprise value: $28.8M

Beyond the preview

Go deeper on Actuate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actuate Therapeutics.

Explore the full profile